Schedule M GMP

After the compliance deadline passed, Himachal Pradesh drug regulators inspected about 90 manufacturing units and found 10 fully compliant and served notices on 80, according to The Tribune, 16 January 2026. That is one state, not a national rate. It does show that a supplier's "Schedule M compliant" label means little without a date and a site attached.

The revised Schedule M requires a pharmaceutical quality system (Part I, §1.1), annual product quality reviews that include export-only products (Part I, §2.3.1), and a contract giver's right to audit the manufacturer (Part I, §9.2.2). A contract giver is the company that hires another manufacturer to make its product. Each of these can be tested in a supplier's documents, and the request list below does exactly that.

This page defines the term, shows where the revised rule stands as of October 2026, and gives a request list you can paste into a request for quotation (RFQ).

Schedule M GMP is the set of good manufacturing practice (GMP) rules in Schedule M of India's Drugs Rules, 1945. It covers premises, plant, equipment, quality systems and records for medicines and active pharmaceutical ingredients (APIs). The current text was notified on 28 December 2023 as G.S.R. 922(E). It substituted the earlier schedule and is titled "Good Manufacturing Practices and Requirements of Premises, Plant and Equipment for Pharmaceutical Products." It governs an Indian manufacturing license, not US FDA acceptance.

Part I sets the main principles, including a pharmaceutical quality system and annual product quality reviews. Later parts add rules by product type: oral solids (Part VIII), oral liquids (Part IX), topicals (Part X) and APIs (Part XII). Part XII applies the Part I principles to API manufacture as well.

As of October 2026, every compliance date in the notification and its extension has passed. The notification gave large manufacturers (turnover above 250 crore rupees) six months and small and medium manufacturers (250 crore or less) twelve months from publication. One crore is 10 million.

The first two dates are calculated from the 28 December 2023 publication date and the notification's six- and twelve-month periods.

The extension needed Form A, the application the Central Drugs Standard Control Organisation (CDSCO) required for the extension, with a section-wise gap analysis and an upgrade plan, as reported by Pharmabiz. On 8 November 2025 CDSCO told state regulators to inspect immediately the units that had not applied for an extension, and to plan inspections of those that had, according to Pharmabiz. Check CDSCO's Gazette notifications page for any later notice before relying on a date.

No. Schedule M is Indian law, and US supply runs on US law. Under 21 CFR 210.1, a drug made in breach of current good manufacturing practice (CGMP) is adulterated. FDA says it inspects manufacturing facilities worldwide, including those making active ingredients. Import Alert 66-40 (revised 15 July 2025) allows detention without physical examination of drugs from firms that have not met drug GMPs.

Schedule M and US supply answer different questions

Schedule M is the floor for an Indian supplier, not the finish line. Three documents get mixed up with it:

• A WHO-GMP certificate is a separate document.
• ICH Q7 is the international GMP guide for APIs.
• FDA drug establishment registration is a US listing, not an Indian one.

Ask for the eight items below. Each has a pass and a fail you can test.

The audit right and technical agreement are the contract side of the rule. A pharmaceutical quality agreement is where you write them down, and the guide to third party manufacturing shows how to build the vetting pack.

Aarise Pharmaceuticals is an API sourcing, supply and export partner for business buyers, and it confirms documentation product by product. Regulatory status and permitted end use depend on the molecule, the manufacturer's documents and the destination country. Buyers confirm local registration and import authorization before commercial supply.

Buyers can add the request list above to their RFQ. Aarise asks for the product or CAS (Chemical Abstracts Service) number, quantity, destination, grade or purity, documents, payment terms and Incoterms (international delivery terms). It shares COA, specifications and SDS/MSDS (safety data sheets) where applicable, per product, and confirms license and site details at quotation. It also supports sample and evaluation quantities for qualified business buyers, and buyers can browse the US pharma raw material catalog first. RFQs go to the sales team, by email at sunil@aarisepharma.com or WhatsApp at +91 9899783330.